Abstract：Objective To investigate the application of SRS MapCHECK (SRS), ArcCHECK (Arc) and Portal Dosimetry (PD) dose
verification systems in the verification of stereotactic treatment plans. Methods A total of 45 tumor patients who received stereotactic
radiotherapy in our hospital were analyzed retrospectively, and the verification plans of SRS, Arc and PD were designed according
to the treatment plan and executed on the Varian VitalBeam linear accelerator. At the 10% dose threshold, the pass rates of the three
dose verification systems under the γ evaluation criteria of 3%/2 mm, 3%/1 mm, 2%/2 mm, 2%/1 mm and 1%/1 mm were recorded.
Results There were significant differences in the γ pass rates of treatment plans obtained by the three dose verification systems under
different evaluation criteria, but there were no significant differences in the γ pass rates obtained by SRS and PD validation at 3%/2
mm and 2%/2 mm evaluation criteria (all P>0.05); and there were no significant differences in the γ pass rates obtained by Arc and
PD validation at 3%/1 mm, 2%/1 mm and 1% /1 mm ( all P>0.05). In determining whether the treatment plan was feasible, SRS was
superior to Arc and PD, and PD was slightly superior to Arc. Conclusion All the three dose verification systems can be used for dose
verification of stereotactic treatment plans, among which SRS has obvious advantages in stereotactic treatment plan verification due
to its high spatial resolution and can be given priority in clinical application. In addition, the more stringent γ evaluation criteria for
SRS dose verification can be 2%/1 mm, and the more stringent γ evaluation criteria for Arc and PD dose verification can be 2%/2
mm or 3%/1 mm.
刘凌湘，黄贤海，张庆钊，陈照辉，易兰. SRS MapCHECK、ArcCHECK及Portal Dosimetry在立体定向治疗计划剂量验证对比[J]. 中国医疗设备, 2022, 37(11): 67-70.
LIU Lingxiang, HUANG Xianhai, ZHANG Qingzhao, CHEN Zhaohui, YI Lan. Comparison of Dose Verification of Stereotactic Treatment Plans Using SRS MapCHECK,
ArcCHECK and Portal Dosimetry. China Medical Devices, 2022, 37(11): 67-70.
